Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer.
Gynecol Oncol
; 178: 27-35, 2023 Nov.
Article
in En
| MEDLINE
| ID: mdl-37748268
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Endometrial Neoplasms
/
Neoplasm Recurrence, Local
Type of study:
Prognostic_studies
Limits:
Aged
/
Female
/
Humans
Language:
En
Journal:
Gynecol Oncol
Year:
2023
Document type:
Article
Affiliation country:
Country of publication: